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ABSTRACT
We report the outcome of 13 patients with advanced malignancies who underwent nonmyeloablative condi-
tioning therapy followed by infusion of partially matched unrelated cord blood cells. The median age of these
patients was 49 years, and their median weight was 65.7 kg. The median nucleated cell dose infused was 2.07
107/kg. Eight of the 13 patients demonstrated donor chimerism between 4 weeks and 6 months, and subse-
quent conversion to full donor chimerism was achieved in 5 patients. Three patients were alive and free of
disease at 158 to 1054 days, with a median survival of 288 days after transplantation. The 100-day event-free
survival is 69%, and overall survival is 77%. At 1 year, the event-free and overall survival was 43%. Treatment-
related mortality observed within the first 100 days after transplantation was low: 1 previously extensively
pretreated patient died of multiorgan failure. This result provides a basis for further exploring this potentially
curative approach to selected patients who lack matched related or unrelated hematopoietic stem cell donors.
© 2004 American Society for Blood and Marrow Transplantation
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Allogeneic hematopoietic stem cell transplanta-
ion (HSCT) as a form of potentially curative immu-
otherapy for patients with malignancies has been
imited by the toxicity of myeloablative preparative
egimens, the lack of matched sibling donors, and
raft-versus-host disease (GVHD). Umbilical cord
lood (UCB) transplantation has demonstrated prom-
sing results in both pediatric and adult patients,
hereby broadening the scope of patients who may
eneﬁt from allogeneic HSCT [1-3]. However, the
esults of UCB transplantation involved the use of
yeloablative preparative regimens that are associated
ith considerable morbidity and mortality and a sig-
iﬁcant delay in immune recovery. Moreover, the
isease of the poor-risk patients entered into these
arly trials has led to disappointing outcomes for most
dult patients. The conclusion that can be drawn thus
ar from these ablative preparatory regimens, consid-
ring that most donor-recipient pairs were HLA-dis-
arate, is that UCB contains a sufﬁcient number ofB&MTematopoietic stem cells (HSC) to achieve engraft-
ent in some adult patients with a lower-than-antic-
pated risk of severe acute GVHD. The use of UCB as
source of stem cells allows allografting to be offered
o more patients, many of whom do not have a
atched sibling or unrelated donor, thus making al-
ogeneic therapy the only chance to cure the under-
ying disease. With the profound inﬂuence of the
CB cell dose (both nucleated cell dose and CD34
ell dose) on engraftment, survival, and treatment-
elated mortality in the adult setting, we have focused
n methods to allow for allogeneic engraftment with
ess treatment-related mortality.
Recently, older recipients of allogeneic HSCT
ave been treated successfully with a variety of less
ntense nonmyeloablative conditioning regimens
4-6]. Given the excellent tolerability of these nonmy-
loablative regimens and the high rate of engraftment,
here has been interest in this transplantation strategy
ith UCB as a source of HSC support after nonmy-
loablative preparative regimens.We and others have previously reported the re-
569
s
s
i
u
w
p
a
e
u
M
P
R
P
p
t
d
s
D
P
C
t
b
m
i
D
a
i
t
a
U
a
a
1
P
c

k
p
t
b
i
n
w
b
c
w
o
3
G
s
t
p
a
o
t
M
o
m
d
G
g
G
f
i
w
t
s
o
r
P
b
t
t
f

w
f
1
S
t
v
M
f
d
a
a
a
f
t
w
v
R
P
t
a
N. J. Chao et al.
5ults of adult patients with advanced malignancies who
uccessfully underwent nonmyeloablative condition-
ng therapy followed by infusion of partially matched
nrelated-donor cord blood cells [7-11]. In this article
e report the clinical outcome of a larger group of 13
atients with advanced malignancies treated with this
pproach. In contrast to the data presented by Barker
t al. [11], all these patients received a single unit of
nrelated donor cord blood cells.
ATERIALS AND METHODS
atient Eligibility
This pilot study was approved by the Institutional
eview Board of Duke University Medical Center.
atients were eligible if they had a condition appro-
riate for allogeneic hematopoietic progenitor cell
ransplantation and did not have a 6/6 or 5/6 related
onor or a 6/6 matched unrelated donor. All patients
igned an approved consent form.
onor Selection
Cord blood searches were performed through the
lacental Blood Program at the New York Blood
enter, the National Marrow Donor Program, and
he Cord Blood Transplantation Study cord blood
anks. Units were chosen according to degree of HLA
atching and cell dose. HLA class I antigens were
dentiﬁed according to serologic or low-resolution
NA typing, and class II antigens were identiﬁed
ccording to high-resolution typing of DRB1. Genetic
dentity at DRB1 took precedence over class I iden-
ity. If more than 1 similarly matched unit was avail-
ble, then the unit with the highest cell dose was used.
nits were scored for matching at class I A and B
ntigens and class II DRB1 alleles. All units contained
minimum cryopreserved nucleated cell dose of 1 
07/kg recipient weight.
reparative Regimen and Transplantation
All patients received ﬂudarabine 30 mg/m2 and
yclophosphamide 500 mg/m2 daily for 4 days (days
5 to 2) with horse antithymocyte globulin 30 mg/
g/d for 3 days (days 3 to 1). After the ﬁrst 10
atients, 200 cGy of total body irradiation was added
o the regimen on day 1. The cryopreserved cord
lood units were transported to the transplant center
n a dry shipper and stored in the vapor phase of liquid
itrogen. The units were thawed in the laboratory and
ashed with 10% dextran and 5% human albumin
efore infusion as previously described [12]. Cell
ounts, viability, and CD3 and CD34 cell counts
ere determined at the time of thawing. A single unit
f cord blood was infused through a central line at 1 to
mL/min on day 0. t
70VHD Prophylaxis and Supportive Care
Acute GVHD prophylaxis consisted of cyclo-
porin A and methylprednisolone for the ﬁrst 8 pa-
ients; the next 5 were given cyclosporine and myco-
henolate mofetil. The methylprednisolone was given
t 0.5 mg/kg/d on days 0 through 4 and 1 mg/kg/d
n days 5 through 20, followed by a daily dose
apered by approximately 0.2 mg/kg/wk thereafter.
ycophenolate mofetil was given at 1 g twice daily
rally. Cyclosporine, steroids, or mycophenolate
ofetil was tapered over several months starting at
ay 180 in patients without evidence of chronic
VHD.
Acute and chronic GVHD were diagnosed and
raded by standard criteria. Grade II to IV acute
VHD was initially treated with high-dose steroids
ollowed by other agents at the discretion of the treat-
ng physician. Granulocyte colony-stimulating factor
as administered at 5 g/kg/d until the absolute neu-
rophil count was1000/L for 3 consecutive days. A
ingle patient received granulocyte-macrophage col-
ny-stimulating factor because of a previous allergic
eaction to granulocyte colony-stimulating factor.
latelets were transfused for counts 10000/L or
leeding, and packed red blood cells were adminis-
ered for hematocrit 30%. Neutropenic fever was
reated with broad-spectrum antibiotics. A weekly test
or cytomegalovirus DNA was obtained through day
100, and patients with positive results were treated
ith ganciclovir (5 mg/kg twice daily for 2 weeks
ollowed by 5 mg/kg daily Monday through Friday for
0 weeks).
tatistical Analysis
A total of 13 sequential patients were included in
he analysis. We estimated overall and event-free sur-
ival throughMarch 1, 2004, according to the Kaplan-
eier product-limit method. We calculated event-
ree survival as the time from transplantation to
isease progression, graft failure (primary or second-
ry), autologous bone marrow recovery, or death from
ny cause, whichever occurred ﬁrst. Patients who were
live and disease free were censored at the date of last
ollow-up visit. Overall survival was calculated from
he time of transplantation to death, and patients who
ere alive were censored at the date of last follow-up
isit.
ESULTS
atient Characteristics
Thirteen patients underwent transplantation be-
ween May 2000 and October 2003. The patient char-
cteristics are described in Table 1. The median age of
hese patients was 49 years (range, 19-62 years), and
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Nonmyeloablative UCB Transplantation in Adults
Bheir median weight was 65.7 kg (range, 42-99 kg).
he diagnoses included relapsed acute lymphoblastic
eukemia (n  3), myelodysplasia (n  2), relapsed
antle cell lymphoma (n  2), metastatic melanoma
n  1), relapsed high-grade lymphoma (n  1), re-
apsed acute myeloid leukemia (n  1), relapsed
odgkin disease (n  1), relapsed low-grade lym-
homa (n 1), and chronic myeloid leukemia (n 1).
raft Characteristics
Details of HLA matching, donor and recipient sex
atching, and cell doses are described in Table 1. No
onor/recipient pairs were mismatched at both DR
able 1. Characteristics of Patients, Grafts, and GVHD Prophylaxis
atient
No.
Age
(y)/
Sex
Weight
(kg) Disease
Previous
Autograft/
No. Prior
Regimens
Status at
Transplanta
1 62/M 65.3 MCL-REL1 No/3 Refractor
2 41/M 66.6 MCL-REF Yes/3 Refractor
3 42/M 89.0 DLCL-REF Yes/4 Refractor
4 54/F 59.3 MDS-AML No/0 Untreated
5 37/F 49.1 Melanoma-REF No/2 Refractor
6 42/F 88.7 MDS-REF No/2 Refractor
7 19/M 61.2 T-ALL-REF No/2 Refractor
8 51/M 53.8 AML-CR3 Yes/4 CR3
9 63/F 78.0 ALL-CR1 No/1 CR1
10 60/F 98.7 CML-CP No/1 CP
11 43/F 63.4 T-ALL-CR3 Yes/3 CR3
12 48/F 75.5 Follicular NHL-REF No/7 Refractor
13 33/F 42.0 Hodgkins-REF Yes/5 Refractor
indicates male; F, female; MCI, mantle cell lymphoma; REL, r
serology; UCB, umbilical cord blood; NC, nucleated cell; GVH
colony-forming unit; NA, not available; MDS, myelodysplasti
lymphoblastic leukemia; CR, complete remission; CP, chronic ph
chronic myeloid leukemia; NHL, non-Hodgkin lymphoma.
HLA antigen disparities between donor and recipient are shown i
able 2. Outcome of 13 Patients after Nonmyeloablative Unrelated Um
atient
No.
Donor
Engraftment
Days to
Neutrophils
>0.5  109/L
Days to
Platelets
>20  109/L
Acute
GVHD
(Grade/Site)
1 100% 12 61 0
2 100% 11 Never* 0
3 No Never* Never* —
4 3% 13 Never* —
5 100% 32 37 III/Gut
6 3.6% 6 Never* —
7 No Never* Never* —
8 No 6 6 —
9 No Never* Never* —
10 3% Never* Never* —
11 100% 24 26 0
12 100% 10 14 I/Gut
13 NE — — —
VHD indicates graft-versus-host disease; CR, complete remission
9Never indicates neutrophil never 0.5  10 /L or platelets never 20 
B&MToci. The median number of nucleated cells infused
er kilogram of recipient weight was 2.07  107
range, 1.07- 5.53  107). After thawing, the median
umber of CD3 cells infused was 4.60  106/kg
range, 2.02- 22.82  106/kg), the median number of
olony-forming units was 5.14  104/kg (range, 0.56-
2.2  104/kg), and the median number of CD34
ells was 1.3  105/kg (range, 0.5-9.6  105/kg).
ngraftment and Chimerism
The clinical outcome is summarized in Table 2.
ight of the 12 evaluable patients demonstrated donor
himerism between 4 weeks and 6 months on micro-
HLA
isparity*
CMV
Status
GVHD
Prophylaxis
UCB
NC
(107/kg)
UCB
CD34
(106/kg)
UCB
CD3
(106/kg)
UCB
CFU
(104/kg)
(A, B)  CSA/P 5.53 0.40 6.98 6.13
(A, DRB1)  CSA/P 2.12 0.08 4.24 NA
(A, DRB1)  CSA/P 2.47 0.96 4.95 22.2
(A, DRB1)  CSA/P 1.83 0.05 2.99 2.54
(A, DRB1)  CSA/P 3.22 0.20 9.29 5.14
(A, B)  CSA/P 1.97 0.06 3.23 0.56
(B, DRB1)  CSA/P 1.07 0.44 22.82 NA
(B)  CSA/P 2.86 0.18 6.54 9.79
(B)  CSA/MMF 2.10 0.08 2.02 3.85
(A, B)  CSA/MMF 2.02 0.05 2.75 NA
(A)  CSA/MMF 1.87 0.04 2.65 8.6
(A, B)  CSA/MMF 2.03 0.08 3.05 6.6
(A, B)  CSA/MMF 3.91 0.14 3.54 10.7
REF, refractory; CMV status, patients’ cytomegalovirus status by
ft-versus-host disease; CSA, cyclosporin A; P, prednisolone; CFU,
rome DLCL, diffuse large-cell lymphoma; T-ALL, T-cell acute
MF, mycophenolate mofetil; AML, acute myeloid leukemia; CML,
theses.
Cord Blood Transplantation
hronic
VHD
(site) Current Status Cause of Death
ronchiolitis
terans, gut)
Dead, day 384 Cerebral infarct,
no lymphoma
No Alive in CR, day 1054 —
— Dead, day 185 Disease progression
— Dead, day 680 Disease progression
No Dead, day 134 Disseminated aspergillosis
— Dead, day 193 Disease progression
— Dead, day 288 Disease progression
— Alive in CR, day 518 —
— Dead, day 315 Disease progression
— Dead, day 360 Disease progression
No Dead, day 33 Sepsis
No Alive in CR, 158 —
— Dead, day 2 Multiorgan failure
not evaluable.
9tion D
y 4/6
y 4/6
y 4/6
4/6
y 4/6
y 4/6
y 4/6
5/6
5/6
4/6
5/6
y 4/6
y 4/6
elapse;
D, gra
c synd
ase; M
n parenbilical
C
G
Yes (b
obli
; NE,
10 /L.
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5atellite polymorphism assay or ﬂuorescent in situ
ybridization for sex-mismatched donor/recipient
airs. Microsatellite polymorphisms were performed
or both myeloid and lymphoid cells (CD3 selection),
nd in all cases the percentage of myeloid and lym-
hoid donor cells was similar. Five patients achieved
ull donor chimerism; 3 patients had a transient, low
evel of donor cells, but these cells did not persist. The
emaining 5 patients never demonstrated any evidence
f donor engraftment. One patient with refractory
odgkin disease died on day2 of multiorgan failure.
f note, 4 of the ﬁrst 5 patients demonstrated engraft-
ent, but several of the following patients did not.
ecause of this, 200 cGy of TBI was added to the
egimen, and 2 of the next 3 patients engrafted; the
hird patient died of multiorgan failure too early to
valuate. For those who engrafted, the median time to
eutrophils 500/L was 12 days (range, 6-34 days).
our patients never experienced a decrease to 500/
L. The median time to platelets 20000/L was 14
ays (range, 6-61 days), and 7 patients did not expe-
ience decreases below this number.
vent-Free and Overall Survival
With a median follow-up of 20 months, the me-
ian event-free survival of the entire group was 288
ays, with a range of 10 to 1054 days. The 100-day
vent-free survival was 69%, and overall survival was
7%. One-year event-free and overall survival was
3%. Three patients were alive and disease free with a
edian follow-up of approximately 2 years. The esti-
ated event-free survival is 24% and overall survival is
2% at 4 years.
raft-versus-Host Disease
Of the 8 patients with engraftment, or of the 5
atients with stable engraftment, GVHD occurred in
patients. In 1 patient, GVHD contributed to the
evelopment of Aspergillus pneumonia, and in the sec-
nd patient, GVHD resolved with steroid treatment.
ne patient developed chronic GVHD that was con-
rolled, but that patient died of complications of a
troke without evidence of disease at autopsy.
oxicity and Causes of Death
Despite extensive prior therapy in most of these
atients, the transplantation was well tolerated, and all
atients were treated in the outpatient setting (after
eceiving the chemotherapy as inpatients). No pa-
ients experienced any unusual or unexpected toxicity.
wo patients died of complications directly related to
his procedure: 1, who had 7 prior regimens for re-
ractory Hodgkin disease, of multiorgan failure, and
nother from overwhelming gram-negative sepsis
hen she was fully recovered hematologically and
eady for discharge home. Mild vomiting occurred in i
72patients, diarrhea in 1 patient, herpes simplex virus
tomatitis in 2 patients, varicella zoster virus infections
n 1 patient, steroid-induced hyperglycemia in 2 pa-
ients, and cyclosporine-related toxicities in 2 patients.
ne patient developed transient cardiac failure that
esolved over the course of several weeks with medical
anagement. Complications related to transient cyto-
enia were uncommon: 2 had febrile neutropenia, and
had grade 3 hemorrhagic cystitis. Preemptive gan-
iclovir was started for cytomegalovirus DNA positiv-
ty in patients, but 2 (11%) developed visceral organ
isease (1 colitis and 1 esophagitis). Disseminated As-
ergillus infection occurred in 2 patients with GVHD
and 12 months after transplantation, and this was
atal in 1 patient. The primary cause of mortality was
rogression of the underlying disease in patients who
id not engraft. It is important to note that in patients
ho did not experience donor cell engraftment, au-
ologous recovery was prompt, and there were no
igniﬁcant sequelae from this preparatory regimen,
xcept for the 1 patient who died on day 2.
ISCUSSION
Unrelated UCB transplantation has recently been
xplored in an increasing number of adult patients
12-23]. The relative ease of procurement and the
ower-than-anticipated risk of severe acute GVHD
as made UCB transplantation an appealing alterna-
ive to bone marrow–derived HSCs. UCB contained a
ufﬁcient number of HSCs to achieve engraftment in
dult patients, with a lower-than-anticipated risk of
evere acute GVHD, even when HLA-disparate grafts
ere infused. The use of UCB as a source of stem cells
llows allografting to be offered to more patients,
any of whom do not have a matched sibling or
nrelated donor to allow allogeneic therapy as the
nly chance to cure the underlying disease. The re-
ults thus far suggest that unrelated donor UCB trans-
lantation can result in long-term disease-free survival
n some of these patients. Similar to the pediatric
eries, clinical experience in the adult patients has also
ocumented the importance of graft cell dose in de-
ermining engraftment and survival. It is hoped that
he advantage of a lower GVHD rate without any
pparent increase in relapse in UCB transplantation
ill offset any adverse effect of reduced cell dose on
urvival. However, treatment-related mortality re-
ains the main obstacle for successful UCB transplan-
ation in adults. This treatment-related mortality is
urther enhanced by the advanced disease stages of
hese patients so that ultimately overall survival be-
omes compromised [24]. Moreover, the prolonged
ancytopenia with delays in neutrophil and platelet
ngraftment after an ablative regimen results in a
arked increase in resources as patients are hospital-zed for many weeks awaiting engraftment.
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Nonmyeloablative UCB Transplantation in Adults
BOne possible method to improve on the treat-
ent-related mortality is the use of nonmyeloablative
tem cell transplantation (NST) or transplantation
ith a reduced-intensity conditioning regimen. Use of
his approach was initially based on the rationale that
he therapeutic beneﬁt of an allogeneic transplanta-
ion is partially related to the crucial immune-medi-
ted graft-versus-malignancy effect. The NST, with
ts low-dose preparative regimens, makes allogeneic
ransplantation applicable to patients with relative
ontraindications to myeloablative regimens. This
ose-reduced conditioning nourished the hope that
atients would experience less transplant-related mor-
ality with fewer infections and less GVHD. This
pproach was based on the hypothesis that the atten-
ated conditioning regimens would (1) decrease the
ucosal and tissue damage, (2) minimize the release of
nﬂammatory cytokines, (3) decease the incidence of
nfections, (4) reduce the incidence of GVHD, and (5)
ltimately allow powerful alloimmune responses to
radicate disease processes while minimizing the ini-
ial treatment-related morbidity and mortality. Given
he excellent tolerance of these nonmyeloablative reg-
mens and the high rate of alloengraftment, there has
een considerable interest in these transplantations
trategies with UCB as a source of HSC support. NST
ith UCB provides an opportunity for immunother-
py for older patients, sicker patients, and patients
ithout suitable donors, who are not eligible for this
otentially curative approach.
However, there is increased concern about graft
ejection with this approach. In NST with adult re-
ated or unrelated donor stem cells, the infusion of
ytokine-mobilized peripheral blood progenitor cells
ith higher cell doses may overcome the rejection
otential, with resultant stable donor cell recovery
ver the autologous recovery [25,26]. This may not be
easible in the setting of UCB transplantation with
onmyeloablative conditioning therapy, because there
re on average 2 logs fewer cells infused than would be
onsidered standard for matched sibling or unrelated
onor transplantation. In addition to the lower cell
ose, there is the added complication of HLA mis-
atching, which increases the risk of graft rejection.
he clinical outcome with this novel approach for 2
atients with malignant lymphoma has been previ-
usly published [7]. By 3 months, both patients had
00% donor engraftment and remained in remission 6
nd 12 months after transplantation. This favorable
utcome demonstrated the feasibility of mismatched
nrelated UCB cells, even with the nonmyeloablative
reparative regimens. This report updates the out-
ome and the results in 13 consecutive patients.
The data presented herein demonstrate clearly
hat engraftment can be achieved. Although engraft-
ent is not universal, it is important to note that the
reparatory regimen is truly nonmyeloablative and T
B&MTot a reduced-intensity regimen. Patients who did not
ngraft promptly recovered their autologous cells.
ith the exception of the 1 patient who died on the
econd day after transplantation, all patients recovered
heir peripheral blood counts either from autologous
ecovery or donor-derived hematopoiesis. It is possi-
le that increasing the preparatory regimen with a
igher chemotherapy dose could lead to more stable
nd sustained engraftment. It is surprising that en-
raftment occurs at all, given that the mononuclear or
tem cell dose is quite limited. In addition, most of the
LA matches were at a 4/6 level, with low-resolution
yping for HLA-A and -B and high-resolution typing
or HLA-DRB1. Thus, it is very likely that the match-
ng is even less ideal than the 4/6 match if high-
esolution molecular HLA-A and -B allele typing is
erformed. Alternatively, it is possible that engraft-
ent occurred speciﬁcally because of the heavy pre-
reatment with chemotherapy in most of the patients.
ith the small numbers of patients, it is not possible
o correlate the level of engraftment with the amount
f previous chemotherapy.
Although the overall results could certainly be
mproved, we are encouraged by these preliminary
ata. The favorable overall and disease-free survival in
ur small series is encouraging given the fact our
atients represent a poor prognostic group with re-
apsed or chemoresistant malignancies for whom no
ther source of stem cells was available for the allo-
eneic transplantation. A review of Table 1 demon-
trates the markedly advanced stage of disease for
ost of the patients, and 8 of 13 patients had refrac-
ory disease. Because this was a phase I trial for en-
raftment only, improving on the types of patients
ith less advanced disease will likely improve on the
verall outcome as well. It is likely that the lack of
ngraftment in those patients with refractory disease
as a consequence of involvement of the bone marrow
ith the underlying disease. The resource utilization
as lower given that most of these patients were
reated as outpatients and that their period of neutro-
enia and thrombocytopenia was similar to that for
ther NST recipients of matched sibling or matched
nrelated donors and was signiﬁcantly shorter than
hat reported for recipients of UCB receiving an ab-
ative regimen. Moreover, patients who did not en-
raft had prompt recovery of their autologous stem
ells. Thus, the overall treatment-related mortality for
hese patients was quite low.
Immune recovery after the nonmyeloablative reg-
men was also analyzed, and this has been previously
escribed [8,27]. In brief, as compared with adult
ecipients of UCB after a myeloablative regimen, the
onmyeloablative UCB transplant recipients had (1)
arlier recovery of CD3 T cells, (2) more naive
CD45RA) T cells, (3) a more diverse and robust
-cell repertoire, and (4) earlier detectable T-cell
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5eceptor excision circle–positive T-cells. The num-
ers of patients who are fully engrafted at 6 months to
year are still limited, and therefore further analyses
f immune recovery will need to await continued
atient accrual to this approach.
Recently, allogeneic unrelated UCB transplanta-
ion after a reduced-intensity conditioning regimen
as been reported by several groups [9-11,13]. In the
argest series, by Barker et al. [11], 43 adult patients
ith high-risk or advanced hematologic malignancies
ere given single- or double-unit UCB infusion after
onditioning with 2 different ﬂudarabine-based regi-
ens. Engraftment exceeded 70%, and the incidence
f grade III to IV acute GVHD was low, at 9%,
espite the use of 1 or 2 HLA antigen–mismatched
rafts in 93% of the patients. The 1-year disease-free
urvival of these high-risk subjects was also favorable
24%-41%). Similar to the series of Barker et al., our
eries consisted of a group of high-risk patients who
ither had extensive prior therapy (had failure with
east 2 lines of chemotherapy or had autologous trans-
lantation) or had poor-risk diseases in which there
ere limited curative options other than allogeneic
SCT.
The results observed in this small series suggest
hat UCB transplantation with a nonmyeloablative
onditioning regimen is well tolerated and is associ-
ted with low early transplant-related mortality. The
avorable results of T-cell recovery after such a pro-
edure suggest that it may be possible to have an
xcellent outcome with such an approach. The future
hallenge will be to develop strategies to optimize the
hance of early and durable engraftment to allow
urther studies of immune reconstitution and other
anipulations to decrease relapse.
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